Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amneal Pharmaceuticals Inc Market Cap
The Amneal Pharmaceuticals Inc (AMRX) share price is expected to increase by 4.77% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered AMRX. Price targets range from $7 at the low end to $10 at the high end. The current analyst consensus for AMRX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AMRX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Amneal Pharmaceuticals Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AMRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Chris Schott JP Morgan | Neutral | $9 | Upgrade | Sep 6, 2024 |
| Balaji Prasad Barclays | Overweight | $10 | Maintains | Aug 13, 2024 |
| Les Sulewski Truist Securities | Buy | $10 | Maintains | Aug 12, 2024 |
| Les Sulewski Truist Securities | Buy | $9 | Reiterates | May 6, 2024 |
| Nathan Rich Goldman Sachs | Buy | $8 | Maintains | May 6, 2024 |
| David Amsellem Piper Sandler | Overweight | $8 | Maintains | Mar 21, 2024 |
| Nathan Rich Goldman Sachs | Buy | $6.25 | Maintains | Mar 4, 2024 |
| Balaji Prasad Barclays | Overweight | $8 | Maintains | Jan 29, 2024 |
| Gregory Fraser Truist Securities | Buy | $7 | Maintains | Nov 8, 2023 |
| Gregory Fraser Truist Securities | Buy | $6 | Reiterates | Sep 6, 2023 |
| Balaji Prasad Barclays | Overweight | $5 | Maintains | Aug 7, 2023 |
| David Amsellem Piper Sandler | Overweight | $5 | Maintains | Aug 7, 2023 |
| Gregory Fraser Truist Securities | Buy | $6 | Maintains | Aug 7, 2023 |
| David Amsellem Piper Sandler | Overweight | $3 | Maintains | May 8, 2023 |
| Gregory Fraser Truist Securities | Buy | $4 | Maintains | Mar 29, 2023 |
| Balaji Prasad Barclays | Overweight | $4 | Maintains | Mar 10, 2023 |
| Nathan Rich Goldman Sachs | Buy | $3 | Maintains | Mar 3, 2023 |
| Gary Nachman BMO Capital | Market Perform | $4 | Maintains | Mar 3, 2023 |
| Nathan Rich Goldman Sachs | Buy | $4 | Maintains | Aug 8, 2022 |
| Nathan Rich Goldman Sachs | Buy | $4.5 | Maintains | May 12, 2022 |
When did it IPO
2018
Staff Count
7,850
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Mr. Chirag K. Patel
Market Cap
$2.69B
In 2023, AMRX generated $2.39B in revenue, which was a increase of 8.20% from the previous year. This can be seen as a signal that AMRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 23 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Amneal has launched CREXONT® (Carbidopa and Levodopa) extended-release capsules for Parkinson's disease treatment, expanding its product offerings in the pharmaceutical market.
Why It Matters - Amneal's launch of CREXONT® could enhance revenue growth and market share in the Parkinson's treatment space, impacting stock performance and investor sentiment.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Amneal Pharmaceuticals and Shilpa Medicare received FDA approval for BORUZUâ„¢, a ready-to-use bortezomib injection for subcutaneous or IV use, streamlining oncology treatment preparation.
Why It Matters - FDA approval of BORUZUâ„¢ enhances Amneal's product lineup, potentially increasing market share in oncology and improving revenue. This could positively impact stock performance and investor sentiment.
Tue, 03 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - AMRX stock increased by 29.3% over the past month following the FDA's approval of its Parkinson's Disease drug, Crexont.
Why It Matters - AMRX's 29.3% stock increase reflects strong market confidence following FDA approval of Crexont, indicating potential revenue growth and enhanced company valuation.
Wed, 21 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Amneal (AMRX) is highlighted as a strong momentum stock that remains reasonably priced, fitting the criteria of the 'Fast-Paced Momentum at a Bargain' screen.
Why It Matters - Amneal (AMRX) shows strong momentum while remaining reasonably priced, indicating potential for growth and value, appealing to investors seeking profitable opportunities.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Amneal Pharmaceuticals received FDA approval for its Propofol Injectable Emulsion in various dosages, enhancing its product portfolio in the anesthesia market.
Why It Matters - FDA approval for Amneal’s Propofol enhances its product portfolio, potentially boosting revenue and market share in the anesthesia segment, which can positively impact stock performance.
Tue, 20 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - LDI, Ltd. has elected Melina Kennedy, CEO of the Central Indiana Corporate Partnership, to its Board of Managers, enhancing its leadership with a focus on strategic investments in Indiana.
Why It Matters - The election of Melina Kennedy to LDI's Board enhances leadership credibility and strategic direction, potentially influencing investment decisions and stakeholder confidence in the firm's initiatives.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
